Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.

BACKGROUND: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to treat macula...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Health Technol Assess
Main Authors: Hykin, Philip, Prevost, A Toby, Sivaprasad, Sobha, Vasconcelos, Joana C, Murphy, Caroline, Kelly, Joanna, Ramu, Jayashree, Alshreef, Abualbishr, Flight, Laura, Pennington, Rebekah, Hounsome, Barry, Lever, Ellen, Metry, Andrew, Poku, Edith, Yang, Yit, Harding, Simon P, Lotery, Andrew, Chakravarthy, Usha, Brazier, John
Formato: Artigo
Idioma:Inglês
Publicado: NIHR Journals Library 2021
Assuntos:
Research Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC8287375/
https://ncbi.nlm.nih.gov/pubmed/34132192
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta25380
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares